NCT06816251

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1893 in Non-Obstructive Hypertrophic Cardiomyopathy

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: Shandong Suncadia Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

This study mainly evaluated the safety and tolerability of HRS-1893 in subjects with non-obstructive hypertrophic cardiomyopathy, and the efficacy and plasma concentrations of different dosing regimens in subjects with non-obstructive hypertrophic cardiomyopathy.

Conditions

• Non-obstructive Hypertrophic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	HRS-1893	HRS-1893 tablet.
DRUG	HRS-1893 placebo	HRS-1893 tablet placebo.

Timeline

• Start date: 2025-02-25
• Primary completion: 2025-08-01
• Completion: 2025-08-01
• First posted: 2025-02-10
• Last updated: 2025-03-05

Locations

1 site across 1 country: China